PROK
HealthcareProKidney Corp. · Biotechnology · $560M
What is ProKidney Corp.?
ProKidney Corp. is a clinical-stage biotechnology company focused on developing cellular therapies for chronic kidney disease. Headquartered in Winston-Salem, North Carolina, the company is working to address a significant unmet medical need in kidney care.
ProKidney is developing Renal Autologous Cell Therapy, a patient-derived cell admixture designed to slow or halt the progression of kidney disease. The lead program targets moderate to severe diabetic kidney disease and is currently in Phase III clinical development, with a separate Phase II trial also underway. An additional Phase I trial is exploring treatment for patients with congenital anomalies of the kidney and urinary tract. The company does not yet generate commercial revenue.
ProKidney was founded in 2021 and is headquartered in Winston-Salem, North Carolina.
- Renal Autologous Cell Therapy (REACT) — lead clinical asset
- Phase III program for diabetic kidney disease
- Phase II trial for moderate to severe kidney disease
- Phase I trial for congenital kidney and urinary tract anomalies
Is PROK a Good Stock to Buy?
UQS Score rates PROK as Poor overall, reflecting the early-stage nature and financial profile typical of pre-revenue clinical biotechs.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's near-term financial structure carries less immediate distress than many peers at a similar stage. Growth is rated Neutral, acknowledging the pipeline's potential without overstating near-term catalysts.
Quality and Moat are both rated Weak, consistent with a company that has no commercial product, no established revenue base, and no durable competitive advantages yet proven in the market. Valuation is rated Elevated, meaning the current price appears to price in optimistic outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PROK pay dividends?
No — ProKidney Corp. does not currently pay a dividend.
ProKidney does not pay a dividend, which is standard for clinical-stage biotechnology companies. All available capital is directed toward funding clinical trials and advancing the pipeline toward potential regulatory approval. Income-focused investors should not expect distributions from PROK in the near term.
When does PROK report earnings?
ProKidney reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, ProKidney's quarterly reports center on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Investors typically focus on pipeline milestones and financing activity.
For the most recent quarter's results and updates, visit ProKidney's investor relations page directly.
PROK Price History
-79.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in ProKidney Corp.?
Based on ProKidney Corp.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PROK Long-term Outlook
ProKidney's fundamental outlook is shaped by its pipeline timeline rather than near-term financial performance. The Neutral Growth rating reflects that meaningful value inflection depends on clinical readouts — particularly from the Phase III diabetic kidney disease program. The Elevated Valuation rating suggests the market may already be pricing in favorable trial outcomes, which introduces meaningful downside if results disappoint. The Good Risk rating provides some reassurance about near-term financial stability, but the path to commercial viability remains long.
Growth drivers
- Positive Phase III clinical trial data for diabetic kidney disease
- Expansion of the REACT platform into additional kidney disease indications
- Potential partnership or licensing deals with larger biopharmaceutical companies
Key risks
- Clinical trial failure or delays in the Phase III program
- Elevated valuation leaving limited margin of safety if milestones slip
- Ongoing capital needs typical of pre-revenue biotech companies
PROK vs Peers
ProKidney operates in the clinical-stage specialty biotech space alongside several small-cap peers also navigating the path from trials to potential commercialization.
Zevra focuses on rare and orphan diseases, giving it a different regulatory pathway and market profile compared to ProKidney's kidney-disease focus.
Climb Bio targets fibrotic and inflammatory diseases, sharing the clinical-stage risk profile but pursuing distinct therapeutic areas.
Ocugen is developing gene therapies for ocular diseases, representing a different modality and disease area within the small-cap biotech universe.
Frequently Asked Questions
What does ProKidney Corp. do?
ProKidney is a clinical-stage biotechnology company developing Renal Autologous Cell Therapy, a patient-derived cell treatment aimed at slowing the progression of chronic kidney disease. Its lead program targets moderate to severe diabetic kidney disease and is currently in Phase III clinical trials.
Does PROK pay dividends?
No, ProKidney does not pay a dividend. As a pre-revenue clinical-stage company, it reinvests all available capital into research and clinical development. Dividend payments are not expected until the company reaches commercial viability, which remains a future milestone.
When does PROK report earnings?
ProKidney reports on a quarterly cadence standard for US-listed companies. Because it is pre-revenue, reports focus on cash position and trial progress rather than traditional earnings. Check ProKidney's investor relations page for the most current schedule.
Is PROK a good stock to buy?
UQS Score rates PROK as Poor overall. The Quality and Moat pillars are both Weak, reflecting the absence of commercial revenue and proven competitive advantages. The Risk pillar is rated Good, offering some near-term stability, but Valuation is Elevated. The complete analysis is available to Pro members.
Is PROK overvalued?
UQS Score's Valuation pillar for PROK is rated Elevated, suggesting the current market price may already reflect optimistic clinical outcomes. For a pre-revenue biotech, this means investors are paying a premium relative to the company's current financial fundamentals. Full valuation metrics are available to Pro members.
How does PROK compare to its competitors?
ProKidney competes in the small-cap clinical-stage biotech space alongside companies like Zevra Therapeutics, Climb Bio, and Ocugen. Each pursues different disease areas and modalities. UQS Score provides side-by-side pillar comparisons for Pro members to evaluate relative quality and risk.
What is PROK's market cap bracket?
PROK is classified as a small-cap stock. This places it in a segment of the market characterized by higher volatility, limited analyst coverage, and greater sensitivity to clinical trial outcomes compared to larger, more established healthcare companies.
Who founded ProKidney Corp.?
ProKidney was founded in 2021. Founding and leadership details are publicly available through the company's official filings and investor relations materials, which provide the most accurate and up-to-date information on its executive team.
Is PROK a long-term quality investment?
UQS Score's long-term quality indicators — Quality and Moat — are both rated Weak for PROK, which is common for pre-revenue clinical biotechs. Long-term quality potential depends heavily on clinical success and eventual commercialization. Pro members can view the full pillar breakdown to assess the complete picture.
What is the main competitive advantage of ProKidney?
ProKidney's potential advantage lies in its autologous cell therapy approach, which uses a patient's own cells to target kidney disease — a condition with limited treatment options. However, UQS Score rates the Moat pillar as Weak, reflecting that this advantage is not yet commercially proven.
What sector does PROK belong to?
PROK belongs to the Healthcare sector, specifically within clinical-stage biotechnology. Companies in this segment are typically pre-revenue and derive their value from pipeline assets and the probability of regulatory approval rather than current financial performance.
Is PROK a growth stock or value stock?
Based on UQS Score's pillar ratings, PROK shows a Neutral Growth profile and an Elevated Valuation — a combination that does not fit neatly into either category. It carries the speculative characteristics of a clinical-stage growth bet, but without the valuation discount typically associated with value investing.
Unlock Full PROK Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare PROK against clinical-stage biotech peers
- ✓Track Quality, Moat, and Risk signals over time
- ✓Get the full valuation context behind the Elevated rating
Pro Analysis
PROK — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 24.9 | 4.9 | 26.0 | 33.9 | 69.4 | 0.0 | -3.3 |
| May 17, 2026 | 28.2 | 8.7 | 26.0 | 33.9 | 84.7 | 0.0 | +3.3 |
| Apr 22, 2026 | 24.9 | 5.5 | 26.0 | 33.9 | 68.6 | 0.0 | -1.7 |
| Apr 3, 2026 | 26.6 | 5.5 | 26.0 | 42.4 | 68.6 | 0.0 | -0.3 |
| Apr 2, 2026 | 26.9 | 5.5 | 26.0 | 43.6 | 68.6 | 0.0 | — |
PROK — Pillar Breakdown
Quality
— 4.9/100 (25%)ProKidney Corp. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 33.9/100 (20%)ProKidney Corp. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.4/100 (15%)ProKidney Corp. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)ProKidney Corp. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 26/100 (25%)ProKidney Corp. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PROK.
Score Composition
Financial Data
More Stock Analysis
How is the PROK UQS Score Calculated?
The UQS (Unified Quality Score) for ProKidney Corp. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses ProKidney Corp.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether ProKidney Corp. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.